methyl 7-methoxy-2-methyl-3H-benzimidazole-4-carboxylate | 201287-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 7-methoxy-2-methyl-3H-benzimidazole-4-carboxylate
• 英文别名: methyl 7-methoxy-2-methyl-1H-benzimidazole-4-carboxylate
• CAS: 201287-42-5
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: WAVHHVYRAKGLLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 7-methoxy-2-methyl-3H-benzimidazole-4-carboxylate 在 aluminum (III) chloride 、 硫酸 作用下， 以 甲苯 为溶剂， 生成 methyl 7-hydroxy-2-methyl-1H-benzimidazole-4-carboxylate
  参考文献：
  名称：

  Structure–activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor

  摘要：

  Design, synthesis and the GSK3 beta inhibitory activities of the 7-hydroxy benzimidazole analogs are described. The solid-phase synthetic route was also developed for preparation of the analogs consisting of the novel ATP competitive scaffold. In addition, the structure-activity relationship of the 7-hydroxy benzimidazole analogs and their biological activities are reported. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.065
• 作为产物：
  描述：

  3-氨基-4-甲氧基苯甲酸甲酯 在 sodium hypochlorite 、 碳酸氢钠 、 对甲苯磺酸 作用下， 生成 methyl 7-methoxy-2-methyl-3H-benzimidazole-4-carboxylate
  参考文献：
  名称：

  2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors

  摘要：

  A new family of PDE4 inhibitors based on a benzimidazole framework is described. Several of these compounds are orally bioavailable and show efficacy in in vivo models of inflammatory disease. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00497-1

文献信息

• [EN] SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE<br/>[FR] COMPOSES AZABICYCLIQUES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PRODUCTION DE TNF ET DE LA PHOTODIESTERASE CYCLIQUE D'AMP
  申请人：RHONE-POULENC RORER LIMITED

  公开号：WO1997048697A1

  公开（公告）日：1997-12-24

  (EN) This invention is directed to physiologically active compounds of formula (I) wherein (i) represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring (ii) is an azaheterocycle, and the ring (iii) represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; wherein R1-R3, A1, Z1, m and n are as defined herein. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.(FR) L'invention concerne des composés efficaces sur le plan physiologique représentés par la formule (I), dans laquelle (i) représente un système de noyaux bicyclique comportant de 10 à 13 éléments, dans lequel le noyau (ii) représente un azahétérocycle et le noyau (iii) représente un noyau azahétéroaryle, ou le noyau de benzène éventuellement substitué par halo; R1, R3, A1, Z1, m et n sont tels qu'ils sont définis dans le descriptif. Ces compositions inhibent la production ou les effets physiologiques de TNF, ainsi que la phosphodiestérase cyclique d'AMP. L'invention concerne également des compositions pharmaceutiques contenant ces composés représentés par la formule (I), leur utilisation pharmaceutique et leurs procédés de préparation.

  该发明涉及具有以下式子(I)的生理活性化合物，其中(i)代表一个具有大约10到13个环成员的双环环系统，在该环(ii)为一个氮杂环，环(iii)代表一个氮杂芳基环或可选地卤代苯环；其中R1-R3，A1，Z1，m和n如本文所定义。这些化合物抑制TNF的产生或生理效应，并抑制环磷酸腺苷酶。该发明还涉及包含式(I)化合物的制药组合物，它们的制药用途以及制备它们的方法。
• Substituted azabicyclic compounds
  申请人：——

  公开号：US20020173527A1

  公开（公告）日：2002-11-21

  This invention is directed to physiologically active compounds of formula (I) 1 wherein 2 represents a bicyclic ring, system, of 9 ring members, in which the ring 3 is an oxazole, and the ring 4 is a benzene ring; R 1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z 1 represents a direct bond R 1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R 2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, hydroxy, —SO 2 NR 4 R 5 , —NR 4 SO 2 R 5 , —NR 4 R 5 , —C(═O)R 5 , —C(═O)C(═O)R 5 , —C(═O)NR 4 R 5 , —C(═O)OR 5 , —O(C═O)NR 4 R 5 , or —NR 4 C(═O)R 5 ; R 3 represents —C(═Z)—N(R 7 )R 6 ; A 1 represents a straight or branched C 1-6 alkylene chain optionally substituted by hydroxyl, alkoxy, oxo, cycloalkyl, aryl or heteroaryl; Z 1 represents a direct bond, an oxygen or sulphur atom or NH; n is zero; and mis 1; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

  本发明涉及公式（I）的生理活性化合物，其中2表示一个由9个环成的双环环系统，在该环3中为噁唑环，环4为苯环; R1表示氢或1至约4个碳原子的直链或支链烷基，可选地被羟基或一个或多个卤素原子取代，或当Z1表示直接键时，R1也可以表示低烯基或低炔基或甲酰基; R2表示氢、烯基、烷氧基、烷基、烷基磺酰基、烷基磺酰基、烷基硫基、芳基、芳基烷氧基、芳基烷基磺酰基、芳基烷基磺酰基、芳基烷基硫基、芳氧基、芳基磺酰基、芳基磺酰基、芳基硫基、氰基、环烯基、环烯基氧基、环烷基、环烷基氧基、羟基、-SO2NR4R5、-NR4SO2R5、-NR4R5、-C(═O)R5、-C(═O)C(═O)R5、-C(═O)NR4R5、-C(═O)OR5、-O(C═O)NR4R5或-NR4C(═O)R5; R3表示-C(═Z)-N(R7)R6; A1表示一条直链或支链C1-6烷基链，可选地被羟基、烷氧基、氧代、环烷基、芳基或杂环芳基取代; Z1表示直接键、氧原子或硫原子或NH; n为零; m为1;及其N-氧化物，以及公式（I）化合物和其N-氧化物的前药体，以及它们的制药可接受的盐和溶剂。这些化合物抑制TNF的产生或生理效应，并抑制环磷酸腺苷磷酸二酯酶。本发明还涉及包括公式（I）化合物的制药组合物，其制药用途和制备方法。
• GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES
  申请人：Matsuo Yo

  公开号：US20110301146A1

  公开（公告）日：2011-12-08

  GSK-3beta inhibitors comprising 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives are provided. For example, the inhibitors have following general formula (I).

  提供了包含7-羟基苯并咪唑-4-基甲酮衍生物的GSK-3beta抑制剂。例如，抑制剂具有以下通式（I）。
• 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same
  申请人：Matsuo Yo

  公开号：US20110263566A1

  公开（公告）日：2011-10-27

  7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives, which are useful for PBK inhibitors, are provided.

  提供了7-羟基苯并咪唑-4-基甲酮衍生物，它们对于PBK抑制剂是有用的。
• SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE
  申请人：RHONE-POULENC RORER LIMITED

  公开号：EP0934307A1

  公开（公告）日：1999-08-11